Gracia Merino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6042148/publications.pdf

Version: 2024-02-01

212478 145109 3,772 66 28 60 citations h-index g-index papers 66 66 66 3563 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Secretion into Milk of the Main Metabolites of the Anthelmintic Albendazole Is Mediated by the ABCG2/BCRP Transporter. Antimicrobial Agents and Chemotherapy, 2022, 66, .	1.4	4
2	Analysis of the interaction between tryptophan-related compounds and ATP-binding cassette transporter G2 (ABCG2) using targeted metabolomics. Food Chemistry, 2021, 344, 128665.	4.2	4
3	Role of eprinomectin as inhibitor of the ruminant ABCG2 transporter: Effects on plasma distribution of danofloxacin and meloxicam in sheep. Research in Veterinary Science, 2021, 136, 478-483.	0.9	2
4	Role of the Abcg2 transporter in plasma levels and tissue accumulation of the anti-inflammatory tolfenamic acid in mice. Chemico-Biological Interactions, 2021, 345, 109537.	1.7	4
5	Abcg2 transporter affects plasma, milk and tissue levels of meloxicam. Biochemical Pharmacology, 2020, 175, 113924.	2.0	10
6	Transporters in the Mammary Glandâ€"Contribution to Presence of Nutrients and Drugs into Milk. Nutrients, 2019, 11, 2372.	1.7	43
7	Role of ABCG2 in Secretion into Milk of the Anti-Inflammatory Flunixin and Its Main Metabolite: In Vitro-In Vivo Correlation in Mice and Cows. Drug Metabolism and Disposition, 2019, 47, 516-524.	1.7	11
8	An altered tissue distribution of flaxseed lignans and their metabolites in Abcg2 knockout mice. Food and Function, 2018, 9, 636-642.	2.1	8
9	Flaxseed-enriched diets change milk concentration of the antimicrobial danofloxacin in sheep. BMC Veterinary Research, 2018, 14, 14.	0.7	11
10	The Breast Cancer Resistance Protein (BCRP/ABCG2) influences the levels of enterolignans and their metabolites in plasma, milk and mammary gland. Journal of Functional Foods, 2017, 35, 648-654.	1.6	13
11	Effect of bovine ABCG2 Y581S polymorphism on concentrations in milk of enrofloxacin and its active metabolite ciprofloxacin. Journal of Dairy Science, 2016, 99, 5731-5738.	1.4	10
12	Effect of bovine ABCG2 polymorphism Y581S SNP on secretion into milk of enterolactone, riboflavin and uric acid. Animal, 2016, 10, 238-247.	1.3	21
13	Allocrite Sensing and Binding by the Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1). Biochemistry, 2015, 54, 6195-6206.	1.2	24
14	ABCG2/BCRP interaction with the sea grass <i>Thalassia testudinum</i> Drug Metabolism and Personalized Therapy, 2015, 30, 251-256.	0.3	1
15	Predicting Activators and Inhibitors of the Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1) Based on Mechanistic Considerations. Molecular Pharmaceutics, 2015, 12, 4026-4037.	2.3	27
16	Short communication: The gain-of-function Y581S polymorphism of the ABCG2 transporter increases secretion into milk of danofloxacin at the therapeutic dose for mastitis treatment. Journal of Dairy Science, 2015, 98, 312-317.	1.4	18
17	Novel <i>in vitro</i> systems for prediction of veterinary drug residues in ovine milk and dairy products. Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment, 2014, 31, 1026-1037.	1.1	15
18	Role of ABCG2 in Transport of the Mammalian Lignan Enterolactone and its Secretion into Milk in Abcg2 Knockout Mice. Drug Metabolism and Disposition, 2014, 42, 943-946.	1.7	23

#	Article	IF	Citations
19	Structural determinants of peripheral O-arylcarbamate FAAH inhibitors render them dual substrates for Abcb1 and Abcg2 and restrict their access to the brain. Pharmacological Research, 2014, 87, 87-93.	3.1	11
20	Inhibition of ABCG2/BCRP transporter by soy isoflavones genistein and daidzein: Effect on plasma and milk levels of danofloxacin in sheep. Veterinary Journal, 2013, 196, 203-208.	0.6	36
21	Effects of triclabendazole on secretion of danofloxacin and moxidectin into the milk of sheep: Role of triclabendazole metabolites as inhibitors of the ruminant ABCG2 transporter. Veterinary Journal, 2013, 198, 429-436.	0.6	22
22	The Gut Microbiota Ellagic Acid-Derived Metabolite Urolithin A and Its Sulfate Conjugate Are Substrates for the Drug Efflux Transporter Breast Cancer Resistance Protein (ABCG2/BCRP). Journal of Agricultural and Food Chemistry, 2013, 61, 4352-4359.	2.4	65
23	Comments on Wassermann et al. (2013): Assessment of ABCG2-mediated transport of xenobiotics across the blood-milk barrier of dairy animals using a new MDCKII in vitro model. Archives of Toxicology, 2013, 87, 1863-1864.	1.9	0
24	The Bovine ATP-Binding Cassette Transporter ABCG2 Tyr581Ser Single-Nucleotide Polymorphism Increases Milk Secretion of the Fluoroquinolone Danofloxacin. Drug Metabolism and Disposition, 2013, 41, 546-549.	1.7	23
25	Reevaluation of the Roles of ABCG2 in the Disposition of Genistein. Drug Metabolism and Disposition, 2012, 40, 2219.1-2219.	1.7	3
26	The Anthelmintic Triclabendazole and Its Metabolites Inhibit the Membrane Transporter ABCG2/BCRP. Antimicrobial Agents and Chemotherapy, 2012, 56, 3535-3543.	1.4	27
27	The ABC membrane transporter ABCG2 prevents access of FAAH inhibitor URB937 to the central nervous system. Pharmacological Research, 2011, 64, 359-363.	3.1	26
28	Involvement of breast cancer resistance protein (BCRP/ABCG2) in the secretion of danofloxacin into milk: interaction with ivermectin. Journal of Veterinary Pharmacology and Therapeutics, 2011, 34, 313-321.	0.6	58
29	Bioavailability of the Glucuronide and Sulfate Conjugates of Genistein and Daidzein in Breast Cancer Resistance Protein 1 Knockout Mice. Drug Metabolism and Disposition, 2011, 39, 2008-2012.	1.7	49
30	Analysis of the effect of the bovine adenosine triphosphate-binding cassette transporter G2 single nucleotide polymorphism Y581S on transcellular transport of veterinary drugs using new cell culture models1. Journal of Animal Science, 2011, 89, 4325-4338.	0.2	29
31	Effect of clotrimazole on microsomal metabolism and pharmacokinetics of albendazole. Journal of Pharmacy and Pharmacology, 2010, 55, 757-764.	1.2	26
32	In Vivo Inhibition of BCRP/ABCG2 Mediated Transport of Nitrofurantoin by the Isoflavones Genistein and Daidzein: A Comparative Study in Bcrp1 â^'/â^' Mice. Pharmaceutical Research, 2010, 27, 2098-2105.	1.7	32
33	Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C. European Journal of Pharmacology, 2010, 644, 41-48.	1.7	34
34	Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. Journal of Pharmaceutical Sciences, 2010, 99, 598-617.	1.6	186
35	Involvement of Breast Cancer Resistance Protein (BCRP1/ABCG2) in the Bioavailability and Tissue Distribution of <i>trans-</i> li>Resveratrol in Knockout Mice. Journal of Agricultural and Food Chemistry, 2010, 58, 4523-4528.	2.4	45
36	Antioxidant Profile of Hyaluronan: Physico-Chemical Features and its Role in Pathologies. Mini-Reviews in Medicinal Chemistry, 2009, 9, 1479-1488.	1.1	21

#	Article	IF	Citations
37	Natural Allelic Variants of Bovine ATP-Binding Cassette Transporter ABCG2: Increased Activity of the Ser581 Variant and Development of Tools for the Discovery of New ABCG2 Inhibitors. Drug Metabolism and Disposition, 2009, 37, 5-9.	1.7	22
38	In vitro and in vivo interaction of moxidectin with BCRP/ABCG2. Chemico-Biological Interactions, 2009, 180, 106-112.	1.7	30
39	Milk secretion of nitrofurantoin, as a specific BCRP/ABCG2 substrate, in assaf sheep: modulation by isoflavones ¹ . Journal of Veterinary Pharmacology and Therapeutics, 2009, 32, 498-502.	0.6	27
40	Fluoroquinolone Efflux Mediated by ABC Transporters. Journal of Pharmaceutical Sciences, 2008, 97, 3483-3493.	1.6	72
41	Involvement of Breast Cancer Resistance Protein (ABCG2) in the Biliary Excretion Mechanism of Fluoroquinolones. Drug Metabolism and Disposition, 2007, 35, 1873-1879.	1.7	85
42	Effects of ischemia–reperfusion on the absorption and esterase metabolism of diltiazem in rat intestine. Life Sciences, 2007, 80, 397-407.	2.0	11
43	Multidrug Transporter ABCG2/Breast Cancer Resistance Protein Secretes Riboflavin (Vitamin B 2) into Milk. Molecular and Cellular Biology, 2007, 27, 1247-1253.	1.1	191
44	Inhibitory effects of different antioxidants on hyaluronan depolymerization. Carbohydrate Research, 2007, 342, 96-102.	1.1	59
45	Absorption and metabolism of albendazole after intestinal ischemia/reperfusion. European Journal of Pharmaceutical Sciences, 2007, 31, 16-24.	1.9	21
46	BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2) TRANSPORTS FLUOROQUINOLONE ANTIBIOTICS AND AFFECTS THEIR ORAL AVAILABILITY, PHARMACOKINETICS, AND MILK SECRETION. Drug Metabolism and Disposition, 2006, 34, 690-695.	1.7	184
47	Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): influence of flavonoids and role in milk secretion in sheep. Journal of Veterinary Pharmacology and Therapeutics, 2006, 29, 279-287.	0.6	83
48	Role of ABC Transporters in Veterinary Drug Research and Parasite Resistance. Current Drug Delivery, 2006, 3, 199-206.	0.8	32
49	Interaction of Probenecid with the Breast Cancer Resistance Protein Transporter (BCRP/ABCG2). Letters in Drug Design and Discovery, 2006, 3, 236-241.	0.4	1
50	The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nature Medicine, 2005, 11, 127-129.	15.2	376
51	Sex-Dependent Expression and Activity of the ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (BCRP/ABCG2) in Liver. Molecular Pharmacology, 2005, 67, 1765-1771.	1.0	144
52	Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis, 2005, 27, 123-130.	1.3	132
53	Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 144-152.	1.3	258
54	TRANSPORT OF ANTHELMINTIC BENZIMIDAZOLE DRUGS BY BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2). Drug Metabolism and Disposition, 2005, 33, 614-618.	1.7	120

#	Article	IF	CITATIONS
55	The Breast Cancer Resistance Protein (BCRP/ABCG2) Affects Pharmacokinetics, Hepatobiliary Excretion, and Milk Secretion of the Antibiotic Nitrofurantoin. Molecular Pharmacology, 2005, 67, 1758-1764.	1.0	203
56	Effect of amphiphilic surfactant agents on the gastrointestinal absorption of albendazole in cattle. Biopharmaceutics and Drug Disposition, 2003, 24, 95-103.	1.1	7
57	Improved LC method to determine ivermectin in plasma. Journal of Pharmaceutical and Biomedical Analysis, 2003, 31, 639-645.	1.4	23
58	Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. International Journal of Pharmaceutics, 2003, 263, 123-132.	2.6	46
59	Ginseng increases intestinal elimination of albendazole sulfoxide in the rat. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2003, 136, 9-15.	1.3	8
60	The Anthelminthic Agent Albendazole Does Not Interact with P-Glycoprotein. Drug Metabolism and Disposition, 2002, 30, 365-369.	1.7	43
61	Effects of netobimin treatment on the glucose and glycogen contents of Echinococcus granulosus cysts from gerbils. Veterinary Research Communications, 2002, 26, 55-59.	0.6	3
62	Protective effects of Panax ginseng on muscle injury and inflammation after eccentric exercise. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2001, 130, 369-377.	1.3	70
63	Pharmacokinetics of netobimin and microsomal metabolism of albendazole in infected gerbils with Echinococcus granulosus. Parasitology Research, 2001, 87, 107-111.	0.6	5
64	Polymorphisms in OATP-C. Journal of Biological Chemistry, 2001, 276, 35669-35675.	1.6	558
65	Determination by capillary zone electrophoresis of berenil, phenamidine, diampron and dibromopropamidine in serum and urine. Biomedical Applications, 2000, 738, 293-303.	1.7	10
66	Bioavailability of albendazole sulphoxide after netobimin administration in sheep: effects of fenbendazole coadministration Research in Veterinary Science, 1999, 66, 281-283.	0.9	6